Publications by authors named "Susan Learned"

Claim this Profile
1
18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
Daniel Rutrick, Susan M Learned, Brent Boyett, David Hassman, Sunita Shinde

J Subst Use Addict Treat· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.
Brent Boyett, Katharina Wiest, Lori D McLeod, Lauren M Nelson, Warren K Bickel, Susan M Learned

Drug Alcohol Depend· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
Walter Ling, Vijay R Nadipelli, Arnie P Aldridge, Naoko A Ronquest, Caitlyn T Solem, Susan M Learned

J Addict Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate metabolism biomarkers from two randomised placebo-controlled clinical studies with paroxetine and venlafaxine.
Lucia Carboni, Bruno Delafont, Elena Ivanchenko, Emiliangelo Ratti, Susan M Learned

World J Biol Psychiatry· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
Anne C Andorn, Barbara R Haight, Sunita Shinde, Paul J Fudala, Yue Zhao, Susan M Learned

J Clin Psychopharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
Walter Ling, Vijay R Nadipelli, Caitlyn T Solem, Naoko A Ronquest, Yu-Chen Yeh, Susan M Learned

J Addict Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.
Walter Ling, Vijay R Nadipelli, Caitlyn T Solem, Naoko A Ronquest, Yu-Chen Yeh, Susan M Learned

J Subst Abuse Treat· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Ruihua Dong, Hongyun Wang, Dandan Li, Liwei Lang, Frank Gray, Susan M Learned

Drugs R D· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.
Lucia Carboni, Dennis J McCarthy, Bruno Delafont, Michele Filosi, Elena Ivanchenko, Susan M Learned

Transl Psychiatry· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study.
Rahul Dhanda, Della Varghese, Vijay R Nadipelli, Maurizio Fava, Namita Joshi, Susan M Learned

Patient Prefer Adherence· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment.
Walter Ling, Vijay R Nadipelli, Caitlyn T Solem, David Farabee, Naoko A Ronquest, Susan M Learned

Subst Abuse Rehabil· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Barbara R Haight, Susan M Learned, Celine M Laffont, Paul J Fudala, Yue Zhao

Lancet· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics.
Walter Ling, Vijay R Nadipelli, Naoko A Ronquest, Victoria A Albright, Arnie P Aldridge, Susan M Learned

Contemp Clin Trials· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
Amir Inamdar, Emilio Merlo-Pich, Michelle Gee, Clare Makumi, Prafull Mistry, Susan Learned

J Psychopharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.
Susan Learned, Ole Graff, Suraja Roychowdhury, Rachel Moate, K Ranga Krishnan

J Psychopharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis